PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-12-01 DOI:10.1080/2162402x.2023.2289738

Mengjia Song, Yue Huang, Ye Hong, Juan Liu, Jia Zhu, Suying Lu, Juan Wang, Feifei Sun, Junting Huang, Jiaqian Xu, Yan Tang, Jian-Chuan Xia, Yizhuo Zhang

引用次数: 0

Abstract

T/NK cell-based immunotherapy has achieved remarkable success in adult cancers but has limited efficacy in pediatric malignancies including high-risk neuroblastoma (NB). Immune defects of NB tumor ...

查看原文本刊更多论文

在神经母细胞瘤中，表达PD-L1的自然杀伤细胞预示着良好的预后和对PD-1/PD-L1阻断的反应

基于T/NK细胞的免疫治疗在成人癌症中取得了显著的成功，但在包括高危神经母细胞瘤(NB)在内的儿科恶性肿瘤中疗效有限。NB肿瘤的免疫缺陷…

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.